Final Pfizer Vaccine Tests Show 95% Efficacy

During the third phase of the trials, the vaccine was confirmed to be effective in preventing symptomatic COVID-19.

Pfizer’s COVID vaccine is 95% effective in final clinical trials. Bloomberg reported this with reference to the company on Wednesday, November 18.

In a third phase of trials, Pfizer and its German partner BioNTech found that the vaccine was 95% effective in preventing symptomatic COVID-19. At the same time, a week earlier, the companies claimed an efficiency of 90%.

The companies said that more than 40,000 adult test subjects who received two doses of the drug had no serious side effects.

The vaccine will now be submitted for regulatory approval in a few days.

Previously, Pfizer announced its intention to apply for approval of the vaccine from the US Food and Drug Administration before the third week of November.

Previously, the American Pfizer and the German BioNTech published data according to which the risk of contracting coronavirus when using their vaccine is reduced by more than 90%.

Even more effective. Second Covid-19 vaccine

News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet